Company intelligence / Profile preview

Protai

Tel Aviv, Tel Aviv District, Israelprotai.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Protai has built an AI-based platform that maps diseases at the protein level to enhance drug discovery. The company has created a large proteomic database with over 50,000 clinical samples and is working on developing precision medicine solutions

Therapeutic areas: OncologyImmunology
Modalities: Small moleculesantibodiesPROTAC and other therapeutic agents
Industry: Biotech

Drug pipeline

5 assets

PRT-003

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

NVIDIA Inception programpartnerships with pharmaceutical companies mentioned but not specified

Beyond the preview

Go deeper on Protai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protai.

Explore the full profile